JS 001

Drug Profile

JS 001

Alternative Names: Anti-PD1 monoclonal antibody - Shanghai Junshi; JS001

Latest Information Update: 08 Jun 2017

Price : $50

At a glance

  • Originator Shanghai Junshi Biosciences
  • Developer Fudan University; Peking University; Shanghai Junshi Biosciences
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Immunomodulators; PDCD 1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Bladder cancer; Malignant melanoma
  • Phase I/II Gastric cancer; Head and neck cancer; Nasopharyngeal cancer; Oesophageal cancer
  • Phase I Breast cancer; Lymphoma; Neuroendocrine tumours; Renal cancer; Solid tumours; Urogenital cancer

Most Recent Events

  • 31 May 2017 Phase-II clinical trials in Malignant melanoma (Adjuvant therapy) in China (IV)
  • 06 Apr 2017 Phase-I clinical trials in Neuroendocrine tumours (Late-stage disease, Second-line therapy or greater, Inoperable/Unresectable, Monotherapy) in China (IV) (NCT03167853)
  • 06 Apr 2017 Phase-II clinical trials in Bladder cancer (Monotherapy, Second-line therapy or greater, Metastatic disease, Late-stage disease) in China (IV) (NCT03113266)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top